MCID: CLN045
MIFTS: 46

Colonic Benign Neoplasm

Categories: Cancer diseases, Cardiovascular diseases, Gastrointestinal diseases

Aliases & Classifications for Colonic Benign Neoplasm

MalaCards integrated aliases for Colonic Benign Neoplasm:

Name: Colonic Benign Neoplasm 12 15
Neoplasm of Colon 12
Colonic Neoplasms 71
Colon Neoplasm 12
Colonic Tumor 12
Colonic Mass 12

Classifications:



External Ids:

Disease Ontology 12 DOID:235
MeSH 43 D003110
NCIt 49 C2953
SNOMED-CT 67 126838000
UMLS 71 C0009375

Summaries for Colonic Benign Neoplasm

Disease Ontology : 12 An intestinal benign neoplasm that is located in the colon.

MalaCards based summary : Colonic Benign Neoplasm, also known as neoplasm of colon, is related to sigmoid neoplasm and colon adenoma. An important gene associated with Colonic Benign Neoplasm is MIR143 (MicroRNA 143), and among its related pathways/superpathways are ERK Signaling and Toll-like Receptor Signaling Pathway. The drugs Lidocaine and Ketamine have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and testes, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Colonic Benign Neoplasm

Diseases related to Colonic Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 626)
# Related Disease Score Top Affiliating Genes
1 sigmoid neoplasm 32.6 KRAS CEACAM5
2 colon adenoma 32.6 MIR18A MIR15A MIR143 LGR5 KRAS APC
3 colorectal cancer 31.4 TP53 SERPINA3 PTGS2 MYC MLH1 MIR20A
4 juvenile polyposis syndrome 31.2 PTGS2 MLH1 APC
5 descending colon cancer 31.1 KRAS HRAS CEACAM5 CDX2
6 transverse colon cancer 31.1 MLH1 KRAS HRAS CEACAM5
7 cecum carcinoma 31.1 MLH1 KRAS HRAS CEACAM5
8 appendix cancer 30.9 TP53 KRAS HRAS CEACAM5 CDX2
9 adenoma 30.9 TP53 PTGS2 MLH1 KRAS CTNNB1 CDX2
10 gastritis 30.8 TP53 PTGS2 CDX2 CCR6
11 colitis 30.7 PTGS2 MLH1 CTNNB1 CCR6
12 intestinal obstruction 30.5 SERPINA3 CEACAM5 CDX2
13 large intestine cancer 30.5 SERPINA3 MIR20A MIR18A MIR15A MIR143 KDM4C
14 hyperplastic polyposis syndrome 30.5 TP53 KRAS APC
15 mismatch repair cancer syndrome 30.4 MLH1 CTNNB1 APC
16 papilloma 30.4 TP53 PTGS2 KRAS CCR6 CCND1
17 appendix adenocarcinoma 30.4 KRAS HRAS CEACAM5 CDX2
18 lymphoma, hodgkin, classic 30.3 MIR20A MIR18A KDM4C CCR6
19 endosalpingiosis 30.3 TP53 KRAS HRAS
20 atrophic gastritis 30.3 TP53 PTGS2 CDX2
21 familial colorectal cancer 30.3 MLH1 APC
22 liposarcoma 30.3 TP53 MYC CTNNB1 CCND1
23 cystadenoma 30.3 SERPINA3 CEACAM5 CCND1
24 tubular adenocarcinoma 30.2 CTNNB1 CEACAM5 CDX2
25 adenocarcinoma 30.2 TP53 PTGS2 MYC MLH1 KRAS HRAS
26 mucinous adenocarcinoma 30.2 TP53 MLH1 KRAS CEACAM5 CDX2
27 gastrointestinal carcinoma 30.2 TP53 CEACAM5 CDX2
28 bone resorption disease 30.2 SERPINA3 H2AC18 CTNNB1 CCR6
29 transitional cell carcinoma 30.1 TP53 PTGS2 MLH1 HRAS CTNNB1
30 adenocarcinoma in situ 30.1 KRAS HRAS CEACAM5 CDX2
31 b-cell lymphoma 30.1 TP53 MYC MIR20A MIR15A CCND1
32 in situ carcinoma 30.1 TP53 SERPINA3 MYC MIR143 HRAS H2AC18
33 prolymphocytic leukemia 30.1 TP53 MYC CCND1
34 thymoma 30.1 TP53 HRAS CTNNB1 CCND1
35 plasma cell neoplasm 30.1 TP53 SERPINA3 MYC CCND1
36 leiomyosarcoma 30.0 TP53 SERPINA3 MYC CCND1
37 endometriosis 30.0 TP53 PTGS2 MIR20A MIR143
38 kaposi sarcoma 30.0 TP53 MYC CTNNB1 CCND1
39 barrett esophagus 30.0 TP53 PTGS2 MYC CTNNB1 CDX2 CCND1
40 ascending colon cancer 30.0 MLH1 KRAS HRAS CEACAM5 CDX2
41 autosomal recessive disease 30.0 SERPINA3 KDM4C H2AC18 CCR6
42 mantle cell lymphoma 29.9 TP53 MYC CTNNB1 CCND1
43 acquired immunodeficiency syndrome 29.9 TP53 MYC HRAS CCR6 CCND1
44 rectum cancer 29.9 MLH1 MIR20A MIR143 KRAS HRAS CEACAM5
45 villous adenoma 29.9 TP53 MLH1 KRAS HRAS CEACAM5 CDX2
46 lymphoma, mucosa-associated lymphoid type 29.9 TP53 MYC KDM4C CCR6 CCND1
47 inflammatory bowel disease 29.9 TP53 PTGS2 MYC MLH1 KRAS HRAS
48 intrahepatic cholangiocarcinoma 29.9 TP53 KRAS CTNNB1 CDX2 CCND1 APC
49 inflammatory myofibroblastic tumor 29.8 TP53 MYC CCND1
50 familial adenomatous polyposis 29.8 TP53 PTGS2 MYC MLH1 KRAS HRAS

Graphical network of the top 20 diseases related to Colonic Benign Neoplasm:



Diseases related to Colonic Benign Neoplasm

Symptoms & Phenotypes for Colonic Benign Neoplasm

MGI Mouse Phenotypes related to Colonic Benign Neoplasm:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 APC CCND1 CCR6 CDX2 CTNNB1 HRAS
2 cardiovascular system MP:0005385 10.18 APC CCND1 CCR6 CDX2 CTNNB1 HRAS
3 endocrine/exocrine gland MP:0005379 10.18 APC CCND1 CDX2 CTNNB1 HRAS KDM4C
4 digestive/alimentary MP:0005381 10.17 APC CCND1 CDX2 CTNNB1 HRAS KRAS
5 integument MP:0010771 10.1 APC CCND1 CTNNB1 HRAS KDM4C KRAS
6 craniofacial MP:0005382 10.06 APC CCND1 CTNNB1 HRAS KRAS LGR5
7 neoplasm MP:0002006 10.03 APC CCND1 CDX2 CTNNB1 HRAS KDM4C
8 no phenotypic analysis MP:0003012 9.7 CTNNB1 HRAS KDM4C KRAS MYC PTGS2
9 normal MP:0002873 9.65 APC CCND1 CCR6 CDX2 CTNNB1 HRAS
10 respiratory system MP:0005388 9.23 CCND1 CTNNB1 HRAS KRAS LGR5 MLH1

Drugs & Therapeutics for Colonic Benign Neoplasm

Drugs for Colonic Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 401)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
3
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
4
Methadone Approved Phase 4 76-99-3 4095
5
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
6
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
7
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
8
Acetaminophen Approved Phase 4 103-90-2 1983
9
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
10
Orphenadrine Approved Phase 4 83-98-7 4601
11
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
12
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
14
Morphine Approved, Investigational Phase 4 57-27-2 5288826
15
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
16
Magnesium oxide Approved Phase 4 1309-48-4 14792
17
Glucagon Approved Phase 4 16941-32-5
18
Panitumumab Approved, Investigational Phase 4 339177-26-3 50070211
19 Analgesics, Non-Narcotic Phase 4
20 Analgesics Phase 4
21 Anti-Inflammatory Agents Phase 4
22 Cyclooxygenase Inhibitors Phase 4
23 Antirheumatic Agents Phase 4
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4
25 Antipyretics Phase 4
26 Sodium Channel Blockers Phase 4
27 Anti-Arrhythmia Agents Phase 4
28 Diuretics, Potassium Sparing Phase 4
29 Neurotransmitter Agents Phase 4
30 Parasympatholytics Phase 4
31 Excitatory Amino Acid Antagonists Phase 4
32 Anesthetics, Dissociative Phase 4
33 Anticonvulsants Phase 4
34 Respiratory System Agents Phase 4
35 Ketorolac Tromethamine Phase 4
36 Cytochrome P-450 Enzyme Inhibitors Phase 4
37 Acetaminophen, hydrocodone drug combination Phase 4
38 Antitussive Agents Phase 4
39 Cholinergic Agents Phase 4
40 Antiparkinson Agents Phase 4
41 Muscarinic Antagonists Phase 4
42 Cholinergic Antagonists Phase 4
43 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
44 Hormone Antagonists Phase 4
45 Gastrointestinal Agents Phase 4
46 Narcotics Phase 4
47 Laxatives Phase 4
48 Cathartics Phase 4
49 Polyethylene glycol 3350 Phase 4
50 Glucagon-Like Peptide 1 Phase 4

Interventional clinical trials:

(show top 50) (show all 803)
# Name Status NCT ID Phase Drugs
1 Preoperative Assessment of Colon Tumor: A Prospective, Blinded Study. Unknown status NCT00114829 Phase 4
2 A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II Microsatellite-Stable or Low-Level Microsatellite-Instability Colon Cancer Unknown status NCT02887365 Phase 4 tegafur-uracil
3 Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial. Unknown status NCT02958566 Phase 4 Acetaminophen;Gabapentin;Orphenadrine;Lidocaine;Marcaine;Ketamine;Methadone;Tramadol;Ketorolac;Morphine Sulfate;Fentanyl;Dilaudid;Hydrocodone-Acetaminophen Tab 5-325 MG;Morphine Sulfate;Fentanyl;Dilaudid;HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET
4 Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV Completed NCT00263055 Phase 4 oxaliplatin
5 Konzentrationen Von Ertapenem in Kolorektalem Gewebe Completed NCT00535652 Phase 4 Ertapenem
6 Compression Anastomosis: Initial Clinical Experience With the ColonRingTM Completed NCT01056913 Phase 4
7 Effect of Postoperative Laxative on Bowel Function After Colonic Surgery Completed NCT00427492 Phase 4 Magnesia;Placebo
8 Tandem Colonoscopy Study of Narrow Band Imaging Versus White Light Examination to Compare Neoplasia Miss Rates Completed NCT00628147 Phase 4
9 An Open Label Study to Evaluate the Safety of Xeloda as Adjuvant Monotherapy in Patients Who Have Undergone Surgery for Colon Cancer, Dukes Stage C. Completed NCT00502671 Phase 4 capecitabine [Xeloda]
10 Effect of Intravenous Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function in Patients With Colon Cancer Completed NCT02231203 Phase 4 Omegaven;Placebo
11 An Expanded Access Program of AvastinTM (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum Completed NCT02582970 Phase 4 5-Fluorouracil;Bevacizumab;Irinotecan;Oxaliplatin
12 Open-label, Efficacy and Safety Study of Bevacizumab (Avastin®) in Combination With XELOX (Oxaliplatin Plus Xeloda®) for the First-line Treatment of Patients With Metastatic Cancer of the Colon or Rectum - 'OBELIX' Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda
13 Role of Glucagon in Outpatient Colonoscopy? A Prospective Double-Blind Randomized Controlled Trial Completed NCT02078726 Phase 4 Glucagon;Placebo
14 Endo-Laparoscopic Approach Versus Conventional Open Surgery in the Management of Obstructing Left-sided Colon Cancer: A Randomized Trial Completed NCT00654212 Phase 4
15 Patient Satisfaction With Propofol for Out Patient Colonoscopy: A Prospective, Randomized, Double-Blind Study Completed NCT02937506 Phase 4 Propofol;Fentanyl Plus Midazolam
16 Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery Completed NCT02314871 Phase 4 Piritramide;Morphine
17 A Prospective, Randomized Controlled Trial Comparing the Efficacy and Patient Tolerability of Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy Completed NCT01170754 Phase 4 PEG-3350 and Gatorade;Golytely 4 liters
18 Preoperative Use of the High Protein ONS vs Immunoenhancing ONS in Gastrointestinal Cancer Patients Undergoing Surgery Recruiting NCT03980704 Phase 4 IMPACT;resource protein
19 A Randomized, Open-label Study to Compare Propofol Anesthesia With Sevoflurane Anesthesia in Terms of Overall Survival in Patients With Surgical Intervention for Either Breast-, Colon- or Rectal Cancer Recruiting NCT01975064 Phase 4 Propofol;Sevoflurane
20 Multicenter Randomized Study in Patients With Colorectal Cancer With Unresectable Metastases. Impact of Resection vs no Resection of the Primary Tumour as a Survival Factor Active, not recruiting NCT02015923 Phase 4 Chemotherapy- scheme
21 Italian Multicenter Prospective Randomized Trial to Compare Additive Hemostatic Efficacy of EndoClot System to Prevent Bleeding After Endoscopic Mucosal Resection or Endoscopic Submucosal Dissection of Lesions in the Gastrointestinal Tract Not yet recruiting NCT02688699 Phase 4
22 Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer Unknown status NCT00295035 Phase 3 CELECOXIB;CURCUMIN
23 The Effectiveness and Safety of Adjuvant Cytokine-induced Killer Cell Immunotherapy for Stage III Colorectal Cancer Patients After Chemotherapy Unknown status NCT02280278 Phase 3 Adjuvant chemotherapy
24 A Randomized Clinical Trial Comparing Laparoscopic and Open Surgery for Colon Cancer Unknown status NCT00387842 Phase 3
25 Microbiological Spectrum of the Intraperitoneal Surface After Elective Right-sided Colon Cancer: Are There Differences in the Peritoneal Contamination After Performing a Stapled or a Handsewn Anastomosis? Unknown status NCT01458353 Phase 3
26 Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts Unknown status NCT00002455 Phase 3
27 The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak and Short-term Outcomes in Robotic Colorectal Surgery: A Prospective Randomized Trial Unknown status NCT02598414 Phase 2, Phase 3
28 Phase III Randomized Study of Intensive Adjuvant Chemotherapy for Resected Colon Cancer at High Risk of Recurrence Unknown status NCT00005979 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
29 Synergistic Anti-tumor Effect of ChangTai Keli Based on Chemotherapy for Colon Cancer Patients:a Randomized, Parallel-group, Double-blind, Multicenter Clinical Study Unknown status NCT02510118 Phase 2, Phase 3 mFOLFOX6;XELOX;Placebo ChangTai Keli;ChangTai Keli
30 The Influence of Micrometastases on Prognosis and Survival in Stage I-II Colon Cancer Patients: The EnRoute+ Study Unknown status NCT01097265 Phase 2, Phase 3 capecitabine;oxaliplatin
31 5-Fluorouracil-Leucovorin With or Without Carboplatin as Adjuvant Treatment for Primary Dukes B2-C Colon Cancer; Chronomodulated Versus Standard Administration. A Multicenter Randomized Phase III Trial of the GRECCR-Belgium (Study 03). Unknown status NCT00046995 Phase 3 carboplatin;fluorouracil;leucovorin calcium
32 A Phase III Randomized Trial Investigating the Duration of Adjuvant Therapy(3 Versus 6 Months) With the Modified FOLFOX 6 or XELOX Regimens for Patients With Stage III Colon Cancer Unknown status NCT00958737 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin;XELOX regimen;Capecitabine
33 Pilot / Phase III Randomized Trial Comparing Standard Systemic Therapy to Cytoreduction + Hyperthermic Intraperitoneal Mitomycin C + Standard Systemic Therapy in Patients With Limited Peritoneal Dissemination of Colon Adenocarcinoma Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
34 A Multicenter Trial Investigating the Duration of Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX Regimen for Patients With High Risk Stage II or Stage III Colon Cancer Unknown status NCT01308086 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Capecitabine;Oxaliplatin;5-Fluorouracil;Leucovorin;Capecitabine;Oxaliplatin;Oxaliplatin
35 Randomized Phase III Intergroup Trial in Resected Stage 2 (Dukes B) Colon Cancer: 6-Month Infusional 5FU-CPT11 (+/- Folinic Acid) Versus Observation - Determination of Biologic Predictive and Response Factors Unknown status NCT00091312 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
36 Randomized Phase III Study Assessing the Interest of Primary Tumor Resection in Patients With Asymptomatic Colon Cancer and Unresectable Synchronous Liver Metastases. Unknown status NCT02363049 Phase 3 Chemotherapy
37 A Randomized Controlled Trial Comparing the Outcomes of Patients Who Undergo Single Port Laparoscopic Colectomy and Conventional Laparoscopic Colectomy for Colonic Neoplasia Unknown status NCT01101672 Phase 2, Phase 3
38 Complete Mesocolic Excision (CME) With Central Supplying Vessel Ligation (CVL) Compared With Conventional Surgery for Colon Cancer: a Double-blinded Randomized Study Unknown status NCT02526836 Phase 2, Phase 3
39 Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer Completed NCT00275210 Phase 3 Oxaliplatin (SR96669)
40 Lymph Node Ratio and Kras Mutation in Risk Stratification of Colon Cancer Completed NCT04342676 Phase 3 Panitumumab
41 BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy Completed NCT00756977 Phase 3 BLI850;polyethylene glycol 3350 based bowel preparation
42 BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy Completed NCT00756548 Phase 3 BLI850;polyethylene glycol 3350 based bowel preparation
43 Post-Approved Phase III Study of 1-LV/5FU Therapy Completed NCT00195585 Phase 3 Isovorin;UFT
44 A Prospectively Randomized Study on Adjuvant Chemotherapy in Patients With Operated Colon Carcinoma Dukes B (Stage II; T3-4, N0, M0). Completed NCT00309543 Phase 3 Fluorouracil;Leucovorin
45 The Effects of Exercise Training on the Health-related Fitness of Colon Cancer Survivors: a Randomized Controlled Trial Completed NCT00813540 Phase 2, Phase 3
46 A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo Completed NCT00056459 Phase 3 Vatalanib
47 A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum Completed NCT00056446 Phase 3 Vatalanib
48 A Prospectively Randomized Phase III Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Patients With Operated Colon Carcinoma Dukes C (Stage III; T1-4, N1-30, M0). Completed NCT00309530 Phase 3 5-fluorouracil, levamisol, interferon
49 Parallel Group Comparison of the New 2 Liter Gut Cleansing Solution NRL 994 Versus Sodium Phosphate Preparation in Routine Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening. Completed NCT00427089 Phase 3 Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate;Sodium Phosphate solution (NaP)
50 First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum First BEAT (Bevacizumab Expanded Access Trial)- Brazilian Extension Completed NCT01169558 Phase 3 Bevacizumab;Fluoropyrimidine-based Chemotherapy

Search NIH Clinical Center for Colonic Benign Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine
Fluorouracil
irinotecan
Irinotecan hydrochloride
Levamisole
Lomustine

Genetic Tests for Colonic Benign Neoplasm

Anatomical Context for Colonic Benign Neoplasm

The Foundational Model of Anatomy Ontology organs/tissues related to Colonic Benign Neoplasm:

19
Colon

MalaCards organs/tissues related to Colonic Benign Neoplasm:

40
Colon, Liver, Testes, Lymph Node, Breast, Lung, Skin

Publications for Colonic Benign Neoplasm

Articles related to Colonic Benign Neoplasm:

# Title Authors PMID Year
1
Danshen improves survival of patients with colon cancer and dihydroisotanshinone I inhibit the proliferation of colon cancer cells via apoptosis and skp2 signaling pathway. 61
28807849 2017
2
Risk analysis for the surgical treatment of colorectal cancer in elderly patients undergoing scheduled and urgent interventions. 61
24670335 2014
3
Role of Sulindac and Celecoxib in the regulation of angiogenesis during the early neoplasm of colon: exploring PI3-K/PTEN/Akt pathway to the canonical Wnt/β-catenin signaling. 61
22397759 2012
4
Chemopreventive effects of non-steroidal anti-inflammatory drugs in early neoplasm of experimental colorectal cancer: an apoptosome study. 61
20623380 2011
5
The role of NF-κB and PPARγ in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors. 61
20514536 2010
6
[Neoplasm of colon, complicated by its partial obstruction in child]. 61
10081257 1999
7
[Epidemiologic panorama of cancer mortality in the Mexican Institute of Social Security: 1991-1995]. 61
9381249 1997
8
[N-acetylation polymorphism versus differentiation of organic susceptibility to carcinogenic effect of homo- and heterocyclic aromatic amines]. 61
7968503 1994

Variations for Colonic Benign Neoplasm

Expression for Colonic Benign Neoplasm

Search GEO for disease gene expression data for Colonic Benign Neoplasm.

Pathways for Colonic Benign Neoplasm

Pathways related to Colonic Benign Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 TP53 PTGS2 MYC KRAS HRAS CTNNB1
2
Show member pathways
13.07 TP53 MYC KRAS HRAS CTNNB1 CCND1
3
Show member pathways
12.96 TP53 PTGS2 MYC KRAS HRAS CTNNB1
4
Show member pathways
12.95 TP53 PTGS2 MYC KRAS HRAS CTNNB1
5
Show member pathways
12.81 TP53 MYC MLH1 KRAS HRAS CTNNB1
6
Show member pathways
12.75 TP53 PTGS2 KRAS HRAS CTNNB1 APC
7 12.75 TP53 PTGS2 MYC MLH1 KRAS HRAS
8
Show member pathways
12.65 TP53 MYC KRAS HRAS CCND1
9
Show member pathways
12.64 TP53 MYC MLH1 KRAS HRAS CTNNB1
10
Show member pathways
12.61 TP53 MYC KRAS HRAS CTNNB1
11
Show member pathways
12.54 TP53 LGR5 KRAS HRAS APC
12
Show member pathways
12.54 TP53 MYC KRAS HRAS CTNNB1
13
Show member pathways
12.44 TP53 MYC LGR5 CTNNB1 CCND1 APC
14
Show member pathways
12.42 PTGS2 KRAS HRAS CTNNB1
15
Show member pathways
12.42 TP53 MYC MIR20A MIR18A CCND1
16 12.42 TP53 PTGS2 MYC CTNNB1 CCND1 APC
17
Show member pathways
12.41 TP53 MYC HRAS CCND1
18 12.38 TP53 MYC CCND1 APC
19 12.37 TP53 MYC KRAS HRAS CCND1
20
Show member pathways
12.35 MYC KRAS HRAS CTNNB1
21
Show member pathways
12.35 TP53 HRAS CTNNB1 CCND1 APC
22
Show member pathways
12.34 MYC HRAS CTNNB1 CCND1
23 12.32 TP53 KRAS HRAS CCND1
24 12.27 TP53 MYC KRAS HRAS CTNNB1 CCND1
25
Show member pathways
12.26 TP53 MYC KRAS HRAS CCND1
26
Show member pathways
12.25 TP53 MYC CTNNB1 CCND1 APC
27 12.19 MYC CTNNB1 CCND1 APC
28 12.19 TP53 MYC KRAS HRAS CCND1
29 12.18 TP53 MYC KRAS CTNNB1 CCND1
30
Show member pathways
12.17 TP53 MYC KRAS HRAS
31 12.13 MYC KRAS HRAS CTNNB1 APC
32 12.06 KRAS HRAS CTNNB1 APC
33 12.04 TP53 PTGS2 MYC CCND1
34 12.02 TP53 PTGS2 MYC CCND1
35 11.96 TP53 MYC KRAS HRAS CTNNB1 CCND1
36 11.91 TP53 PTGS2 MYC CCND1
37 11.86 TP53 MYC KRAS HRAS CTNNB1 CCND1
38 11.85 TP53 PTGS2 MYC MIR20A MIR18A MIR15A
39 11.82 MYC CTNNB1 CCND1 APC
40 11.79 PTGS2 MYC CCND1
41 11.78 TP53 PTGS2 MYC MLH1 KRAS CTNNB1
42 11.76 TP53 MYC KRAS HRAS
43 11.75 TP53 MYC KRAS HRAS CTNNB1 CCND1
44 11.73 TP53 KRAS HRAS
45 11.72 MYC CTNNB1 APC
46 11.71 TP53 MYC HRAS
47 11.69 TP53 MYC KRAS HRAS CCND1
48 11.64 KDM4C CTNNB1 CCND1
49 11.61 TP53 CCND1 APC
50 11.61 MYC CTNNB1 CCND1 APC

GO Terms for Colonic Benign Neoplasm

Biological processes related to Colonic Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 cellular response to DNA damage stimulus GO:0006974 9.99 TP53 MYC MLH1 CCND1 APC
2 positive regulation of apoptotic process GO:0043065 9.88 TP53 PTGS2 MIR15A CTNNB1 APC
3 regulation of cell proliferation GO:0042127 9.87 TP53 PTGS2 LGR5 CTNNB1
4 response to drug GO:0042493 9.85 TP53 PTGS2 MYC CTNNB1 CCND1
5 negative regulation of gene expression GO:0010629 9.8 TP53 MYC MIR20A HRAS CTNNB1
6 Ras protein signal transduction GO:0007265 9.75 TP53 KRAS HRAS
7 response to glucocorticoid GO:0051384 9.73 PTGS2 KRAS CCND1
8 cell cycle arrest GO:0007050 9.73 TP53 MYC HRAS APC
9 cytokine-mediated signaling pathway GO:0019221 9.72 TP53 PTGS2 MYC KRAS CCND1
10 positive regulation of epithelial cell proliferation GO:0050679 9.71 MYC HRAS CCND1
11 cellular response to UV GO:0034644 9.67 TP53 PTGS2 MYC
12 positive regulation of gene expression GO:0010628 9.63 TP53 MYC KRAS KDM4C HRAS CTNNB1
13 ovulation GO:0030728 9.58 PTGS2 MYC
14 response to estradiol GO:0032355 9.56 PTGS2 MYC CTNNB1 CCND1
15 mitotic G1 DNA damage checkpoint GO:0031571 9.55 TP53 CCND1
16 response to isolation stress GO:0035900 9.52 KRAS HRAS
17 re-entry into mitotic cell cycle GO:0000320 9.51 MYC CCND1
18 negative regulation of cell proliferation GO:0008285 9.43 TP53 PTGS2 MIR15A HRAS CTNNB1 APC
19 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.37 MIR20A MIR143
20 positive regulation of cell proliferation GO:0008284 9.23 PTGS2 MYC KRAS KDM4C HRAS CTNNB1

Molecular functions related to Colonic Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.1 TP53 PTGS2 MLH1 KDM4C CTNNB1 CCND1

Sources for Colonic Benign Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....